You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥-B(02142.HK):與阿斯利康訂立新型腫瘤靶向療法的許可及選擇權協議

格隆匯5月23日丨和鉑醫藥-B(02142.HK)發佈公吿,公司全資附屬公司諾納生物(蘇州)有限公司(“諾納生物”),已就將用於創建腫瘤靶向療法的臨牀前單克隆抗體與阿斯利康(LSE╱STO╱Nasdaq:AZN)(“阿斯利康”)訂立許可及選擇權協議。

根據協議,諾納生物將:於交易完成時收取1900萬美元的預付款;收取1000萬美元的近期里程碑付款;於完成特定的開發、監管及商業里程碑時,收取最高5.75億美元的里程碑付款;及收取按淨銷售額支付的分級特許權使用費。此外,倘阿斯利康行使該等選擇權,諾納生物有資格就選擇權計劃收取付款。

協議標誌着公司的Harbour Mice®平台業務發展的重要里程碑,驗證了公司技術平台的潛力及創新能力。公司亦將利用該機會,透過其創新合作模式進一步加強其全球合作網絡,並最大化公司技術平台的科學和商業價值。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account